Comparison of Ramosetron and Granisetron for the Prevention of Acute and Delayed Emesis in Cisplatin-Based Chemotherapy: a Randomized Controlled Trial

Abstract

Ramosetron is effective and safe for the control of acute and delayed emesis induced by cisplatin.

Efficacy, Safety and Quality of Life Outcomes of Palonosetron, Ramosetron and Granisetron as a Part of Antiemetic Therapy in Prevention of Chemotherapy Induced Nausea and Vomiting- A Randomised Comparative Trial

“…Similar findings have been observed in other trials as well. 11,14 In the present study, the ramosetron group showed a better impact on the quality of life than palonosetron and granisetron in both the acute and delayed phases which can be correlated with better complete response rates in the acute and delayed phases and better control of nausea than palonosetron and granisetron. The mean FLIE questionnaire scores in the acute and delayed phases were better in ramosetron group and a higher proportion of patients showed no impact on daily living (NIDL) as defined by a FLIE score of >108 in both the acute and delayed phases.…”

“…Previous studies comparing ramosetron and granisetron for prevention of acute and delayed emesis have revealed similar efficacies and concluded that the two drugs may be used interchangeably for preventing CINV. 11,14 In a study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in Chinese population, palonosetron consistently produced numerically higher complete response rates than granisetron in the acute phase and delayed phase, though the differences were not significant. 15 In a comparative study of antiemetics for the prevention of postoperative nausea and vomiting after laparoscopic gynaecologic surgery, the number of complete responders at 48 h after the surgery was maximum for ramosetron, though the differences between the groups were not statistically significant.…”

“…17 Some comparative trials have also corroborated these findings. 14,15 Chemotherapeutic agents release 5-HT from enterochromaffin cells which activate 5-HT3 receptors on visceral afferent fibres to induce emesis. 5-HT3 receptor antagonists block the activity of 5-HT3 receptors in gut as well as in area postrema, CTZ and vomiting centre.…”

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

“…Ramosetron administered alone was as effective as granisetron or ondansetron for CINV prevention in clinical trials [10][11][12]. In combination with dexamethasone, ramosetron showed a 77% CR rate in acute period, which is comparable to that of granisetron (82%) [16].…”

Comparative study of effects of ramosetron and ondansetron on global satisfaction of patients on cisplatin chemotherapy in head and neck cancers

“…10 Ramosetron has been introduced for the treatment of irritable bowel syndrome (IBS), chemotherapy (cisplatin)-induced nausea and vomiting and late in post-operative nausea and vomiting, with almost no study done for comparing the level of satisfaction of patients receiving this drug with other antiemetics. [11][12][13] Patient satisfaction is very important in modern health care system. Though, it is difficult to assess as no golden standard is available, still one of the methods is by using visual analogue scale (VAS) scoring.…”